A phase I open-label clinical trial to study drug-drug interactions of Dorzagliatin and Sitagliptin in patients with type 2 diabetes and obesity

This is a phase 1, open-label, single-sequence, multiple-dose, single-center trial conducted in the US (NCT03790839), to evaluate the clinical pharmacokinetics, safety and pharmacodynamics of dorzagliatin co-administered with sitagliptin in patients with T2D and obesity. The trial has completed. 15...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Li, Zhang, Jiayi, Sun, Yu, Zhao, Yu, Liu, Xiang, Fang, Zhiyin, Feng, Lingge, He, Bin, Zou, Quanfei, Tracey, Gregory J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10014962/
https://www.ncbi.nlm.nih.gov/pubmed/36918550
http://dx.doi.org/10.1038/s41467-023-36946-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10014962/
https://www.ncbi.nlm.nih.gov/pubmed/36918550
http://dx.doi.org/10.1038/s41467-023-36946-7

Ejemplares similares